Medifast (NYSE:MED – Get Free Report) had its price objective decreased by stock analysts at DA Davidson from $17.00 to $16.50 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the specialty retailer’s stock. DA Davidson’s price target suggests a potential upside of 15.06% from the company’s current price.
Medifast Price Performance
Shares of MED opened at $14.34 on Wednesday. The firm has a market capitalization of $156.88 million, a price-to-earnings ratio of 79.67 and a beta of 1.14. The firm’s fifty day simple moving average is $16.36 and its 200-day simple moving average is $17.99. Medifast has a twelve month low of $13.57 and a twelve month high of $44.72. The company has a current ratio of 3.11, a quick ratio of 2.55 and a debt-to-equity ratio of 0.06.
Medifast (NYSE:MED – Get Free Report) last posted its earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.26. The firm had revenue of $119.00 million for the quarter, compared to analyst estimates of $114.25 million. Medifast had a return on equity of 10.66% and a net margin of 0.35%. Equities analysts forecast that Medifast will post 0.51 EPS for the current fiscal year.
Institutional Trading of Medifast
About Medifast
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Read More
- Five stocks we like better than Medifast
- Most Volatile Stocks, What Investors Need to Know
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Insider Buying Explained: What Investors Need to Know
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- How to Calculate Stock Profit
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.